TuberculosisNCT00172783
PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period
An observational study of Tuberculosis, run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period. Read more about this study
- Who is it for?
- Ages 3 months to 15 yearsHealthy volunteers can take part
- Conditions the study is for
- Tuberculosis
- How many people
- 460 participants
- Where
- 1 siteTaiwan
- Study dates
- Jun 2005to Dec 2005
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 months to 15 years
- All sexes
- Healthy volunteers accepted
- Child
Inclusion Criteria: A healthy child with the age between 3 month to 15 year, who has received BCG in the first month of life as schedule, without history of exposure of tuberculosis. -
Exclusion Criteria: Children not received his BCG within one month after birth, immunodeficiency, received steroid or immunosuppresant within 6 weeks, severe infection within 6 weeks, received life vaccine within 6 weeks
-
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei, 100
Li-Ming Huang, MD, PHD, 886-2-23123456 ext. 5139, lmhuang@ha.mc.ntu.edu.tw
Pei-Chun Chan, MD
About this study
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period.
Read the detailed description
Sampling
- Age under 3 year-old: a targeted population contains 500 children will be used for sampling of this group. This cohort were firstly enrolled for a trial of oral Rota vaccine since 2004. They will be followed up in the cohort up to 2006. Sixty children will be enrolled in the group younger than 1 year-old (1-2, 2-3 year-old, 20 children will be enrolled in each age group).
- Age of 3 to 5 year-old, cases will be enrolled from volunteered students from kindergarden (3-4, 4-5, 5-6 year-old, 20 children will be enrolled in each age group)
- Age of 6 to 15 year-old, cases will be enrolled from volunteered students from elementary school and junior high school ( 30 children will be enrolled in each age group). A total of 300 children will be enrolled from children between 6 year-old and 15 year-old.
- A total of 460 children between the age of 3 month and 15 y/o will be enrolled.
Procedure of PPD test Children who fit the criteria will be given 0.1 ml of PPD (PPD RT23, 2 units) intradermally, in accordance with the guidelines recommended by WHO (17). The tuberculin for the tests is obtained from Denmark and is used throughout the country. PPD indurations will be read 48 to 72 h after administration at 90 degrees from the longest axis of the arm and recorded to the nearest millimeter. Indurations <=5 mm in diameter are classified as negative, those >5 but <=10 mm as doubtful and those >10 mm as positive according to previous consensus (2). All size of indurations will be recorded for further analysis other than arbiturary classification.
Procedure of ELISPOT assay to detect T cells specific for M. tuberculosis antigens 4 ml whole blood is collected in a heparinized tube first and are processed and scored by two scientists who had no access to personal identifiers or TST results within four hours after collection. We amplified the esat-6 gene from genomic DNA isolated from M bovis strain AN5 by PCR, and cloned it into plasmid vector pET21d (Novagen, Madison, WI, USA). Escherichia coli was transformed with this vector. Recombinant ESAT-6 was recovered from transformed E coli and purified by nickel-affinity chromatography. We did ex-vivo interferon-gamma ELISPOT assays, with 300 000 peripheral blood mononuclear cells per well (14,18). We used purified recombinant ESAT-6 and PPD, in addition to negative controls (no added antigen) and positive controls (phytohaemagglutinin). Positive ESAT-6 test wells were defined as containing at least ten spot-forming cells more than, and at least twice as many as, negative control wells-a detection threshold of one per 30 000 peripheral blood mononuclear cells. Assays were done and independently scored by two scientists who were unaware of exposure category and TST results of contacts. ELISPOT assay wells containing more than 300 spot-forming cells cannot be counted accurately because the spots coalesce. 300 cells per well (equivalent to 1000 cells per million peripheral blood mononuclear cells) was therefore taken as the upper limit for accuracy (15).
Exclusion and Follow-up steps Children who are found to have positive PPD test (>10 mm), have a PPD size in the range of 1st 2.5 percentile or having a positive ELISPOT result at the time of enrollment, will be closely followed up for clinical symptoms and signs of TB and necessary diagnostic workup will be done. If LTBI is highly suspected, prophylaxis will be initiated. Closed contact families and care-givers will be asked to take CXR for excluding active pulmonary TB.
Information collection at the enrollment Cross-sectional study of 160 children will be conducted. Children were examined and assessed for general health condition, BCG vaccination record, and BCG scar over L't arm (19). Possible TB exposure including elderly with chronic cough or unexplained prolonged febrile illness in house-hold contact, any contact history with documented open TB will be thoroughly evaluated. Children with suspicious immuno-compromised status, active lung disease or exposure history of TB will be excluded and follow-up will be done.
Biostatistic method Descriptive analysis will be used for size of PPD and result of ELISPOT. P value is calculated with student t test or Chi-square or Fisher exact test for statistic significance (Version 10.0, SPSS, SPSS Inc. Illinois) between different age group. 95%CI will be calculated for the purpose of cut off value of PPD size (except those with unexpected-found TB disease).
- Conditions
- Tuberculosis
- Keywords
- TB, PPD, ELISPOT, BCG
- Medical subject headings
- Tuberculosis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2005 (estimated)
- Study startJun 2005
- Study completionDec 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Other
- Enrolment
- 460 participants
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Li-Ming Huang, MD, PHD, Study chair, National Taiwan University Hospital, Pediatrics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00172783
- Sponsor's protocol ID
- 940201
- Status last verified
- Jun 2005
- First submitted
- 12 Sep 2005
- Last updated
- 15 Sep 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period
- ClinicalTrials.gov ID
- NCT00172783
- Acronym / sponsor ID
- 940201
- Conditions
- Tuberculosis
- Keywords
- TB, PPD, ELISPOT, BCG
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 460 participants
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Jun 2005
- Study completion
- Dec 2005
- First posted
- 15 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period.
Detailed description
Sampling
- Age under 3 year-old: a targeted population contains 500 children will be used for sampling of this group. This cohort were firstly enrolled for a trial of oral Rota vaccine since 2004. They will be followed up in the cohort up to 2006. Sixty children will be enrolled in the group younger than 1 year-old (1-2, 2-3 year-old, 20 children will be enrolled in each age group).
- Age of 3 to 5 year-old, cases will be enrolled from volunteered students from kindergarden (3-4, 4-5, 5-6 year-old, 20 children will be enrolled in each age group)
- Age of 6 to 15 year-old, cases will be enrolled from volunteered students from elementary school and junior high school ( 30 children will be enrolled in each age group). A total of 300 children will be enrolled from children between 6 year-old and 15 year-old.
- A total of 460 children between the age of 3 month and 15 y/o will be enrolled.
Procedure of PPD test Children who fit the criteria will be given 0.1 ml of PPD (PPD RT23, 2 units) intradermally, in accordance with the guidelines recommended by WHO (17). The tuberculin for the tests is obtained from Denmark and is used throughout the country. PPD indurations will be read 48 to 72 h after administration at 90 degrees from the longest axis of the arm and recorded to the nearest millimeter. Indurations <=5 mm in diameter are classified as negative, those >5 but <=10 mm as doubtful and those >10 mm as positive according to previous consensus (2). All size of indurations will be recorded for further analysis other than arbiturary classification.
Procedure of ELISPOT assay to detect T cells specific for M. tuberculosis antigens 4 ml whole blood is collected in a heparinized tube first and are processed and scored by two scientists who had no access to personal identifiers or TST results within four hours after collection. We amplified the esat-6 gene from genomic DNA isolated from M bovis strain AN5 by PCR, and cloned it into plasmid vector pET21d (Novagen, Madison, WI, USA). Escherichia coli was transformed with this vector. Recombinant ESAT-6 was recovered from transformed E coli and purified by nickel-affinity chromatography. We did ex-vivo interferon-gamma ELISPOT assays, with 300 000 peripheral blood mononuclear cells per well (14,18). We used purified recombinant ESAT-6 and PPD, in addition to negative controls (no added antigen) and positive controls (phytohaemagglutinin). Positive ESAT-6 test wells were defined as containing at least ten spot-forming cells more than, and at least twice as many as, negative control wells-a detection threshold of one per 30 000 peripheral blood mononuclear cells. Assays were done and independently scored by two scientists who were unaware of exposure category and TST results of contacts. ELISPOT assay wells containing more than 300 spot-forming cells cannot be counted accurately because the spots coalesce. 300 cells per well (equivalent to 1000 cells per million peripheral blood mononuclear cells) was therefore taken as the upper limit for accuracy (15).
Exclusion and Follow-up steps Children who are found to have positive PPD test (>10 mm), have a PPD size in the range of 1st 2.5 percentile or having a positive ELISPOT result at the time of enrollment, will be closely followed up for clinical symptoms and signs of TB and necessary diagnostic workup will be done. If LTBI is highly suspected, prophylaxis will be initiated. Closed contact families and care-givers will be asked to take CXR for excluding active pulmonary TB.
Information collection at the enrollment Cross-sectional study of 160 children will be conducted. Children were examined and assessed for general health condition, BCG vaccination record, and BCG scar over L't arm (19). Possible TB exposure including elderly with chronic cough or unexplained prolonged febrile illness in house-hold contact, any contact history with documented open TB will be thoroughly evaluated. Children with suspicious immuno-compromised status, active lung disease or exposure history of TB will be excluded and follow-up will be done.
Biostatistic method Descriptive analysis will be used for size of PPD and result of ELISPOT. P value is calculated with student t test or Chi-square or Fisher exact test for statistic significance (Version 10.0, SPSS, SPSS Inc. Illinois) between different age group. 95%CI will be calculated for the purpose of cut off value of PPD size (except those with unexpected-found TB disease).
Study design
- Time perspective
- Other
Who may qualify
- Ages
- 3 months to 15 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2005.
Related trials for Tuberculosis
RecruitingPhase 4
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Mycobacterium Avium Complex Pulmonary Disease
RecruitingObservational study
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Tuberculosis
Not yet recruitingPhase 2
Re-evaluating the Duration in Children of TB Treatment
Tuberculosis
RecruitingPhase 1/2
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Tuberculosis
Active, not recruitingPhase 3
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Tuberculosis, MDR
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Li-Ming Huang, MD, PHD study chair
National Taiwan University Hospital, Pediatrics
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tuberculosis, run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Sep 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Li-Ming Huang, PHD (886-2-23123456 ext. 5139, lmhuang@ha.mc.ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2005.